ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

SEHK:1541 Stock Report

Market Cap: HK$2.6b

ImmuneOnco Biopharmaceuticals (Shanghai) Management

Management criteria checks 3/4

ImmuneOnco Biopharmaceuticals (Shanghai)'s CEO is Wenzhi Tian, appointed in Jun 2015, has a tenure of 9.92 years. total yearly compensation is CN¥25.66M, comprised of 11.5% salary and 88.5% bonuses, including company stock and options. directly owns 17.27% of the company’s shares, worth HK$448.02M. The average tenure of the management team and the board of directors is 3 years and 4 years respectively.

Key information

Wenzhi Tian

Chief executive officer

CN¥25.7m

Total compensation

CEO salary percentage11.5%
CEO tenure9.9yrs
CEO ownership17.3%
Management average tenure3yrs
Board average tenure4yrs

Recent management updates

Recent updates

Why Investors Shouldn't Be Surprised By ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) 27% Share Price Surge

Apr 01
Why Investors Shouldn't Be Surprised By ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) 27% Share Price Surge

Here's Why ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Can Manage Its Debt Despite Losing Money

Mar 26
Here's Why ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Can Manage Its Debt Despite Losing Money

Health Check: How Prudently Does ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Use Debt?

Jun 10
Health Check: How Prudently Does ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) Use Debt?

CEO Compensation Analysis

How has Wenzhi Tian's remuneration changed compared to ImmuneOnco Biopharmaceuticals (Shanghai)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024CN¥26mCN¥3m

-CN¥316m

Sep 30 2024n/an/a

-CN¥345m

Jun 30 2024n/an/a

-CN¥374m

Mar 31 2024n/an/a

-CN¥377m

Dec 31 2023CN¥44mCN¥3m

-CN¥379m

Sep 30 2023n/an/a

-CN¥371m

Jun 30 2023n/an/a

-CN¥362m

Mar 31 2023n/an/a

-CN¥382m

Dec 31 2022CN¥56mCN¥2m

-CN¥403m

Dec 31 2021CN¥8mCN¥2m

-CN¥733m

Compensation vs Market: Wenzhi's total compensation ($USD3.53M) is above average for companies of similar size in the Hong Kong market ($USD394.28K).

Compensation vs Earnings: Wenzhi's compensation has been consistent with company performance over the past year.

CEO

Wenzhi Tian (59 yo)

9.9yrs

Tenure

CN¥25,655,000

Compensation

Dr. Wenzhi Tian is Founder of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. since June 2015 and serves as its Chief Scientific Officer since June 18, 2018 and serves as its Director since June 18, 2015. Dr...

Leadership Team

NamePositionTenureCompensationOwnership
Wenzhi Tian
Founder9.9yrsCN¥25.66m17.27%
HK$ 448.0m
Song Li
VP of Research & Development and Executive Director2.3yrsCN¥1.02mno data
Mei Guan
Joint Company Secretary3yrsCN¥814.00kno data
Xiaodong Gan
Counselless than a yearno datano data
Zikai Xiong
Senior Vice President3.2yrsno datano data
Ruliang Zhang
Deputy GM & Senior VP8.3yrsno datano data
Kin Wai Li
Joint Company Secretary2.9yrsno datano data

3.0yrs

Average Tenure

41yo

Average Age

Experienced Management: 1541's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wenzhi Tian
Founder9.9yrsCN¥25.66m17.27%
HK$ 448.0m
Song Li
VP of Research & Development and Executive Director9.4yrsCN¥1.02mno data
Mei Guan
Joint Company Secretary1yrCN¥814.00kno data
Zhenping Zhu
Independent Non-Executive Director8.8yrsno datano data
Cong Xu
Non-Executive Director4.6yrsno datano data
Kendall Arthur Smith
Independent Non-Executive Director2.9yrsCN¥356.00kno data
Chi Tat Yeung
Independent Non-Executive Director2.9yrsCN¥274.00kno data
Miao Tian
Chairman of Supervisory Committee7.8yrsno datano data
Zimeng Zhao
Employee Representative Supervisor3.3yrsno datano data
Wei Zhang
Employee Representative Supervisorless than a yearno datano data

4.0yrs

Average Tenure

39.5yo

Average Age

Experienced Board: 1541's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/03 13:05
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sean WuMorgan Stanley